NCT04430894: Phase 2: KRDI in Transplant-Eligible MM

• NCT04430894: Phase 2: KRDI in Transplant-Eligible MM

KRDI in Transplant-Eligible MM

This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant.

The names of the study drugs involved in this study are:

Carfilzomib

Isatuximab

Lenalidomide

Dexamethasone

Sponsor:

Massachusetts General Hospital

Collaborators:

Amgen

Sanofi

---

ClinicalTrials.gov Identifier: NCT04430894

Official Title: A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

First Posted: June 12, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: Carfilzomib

Drug: Isatuximab

Drug: Lenalidomide

Drug: Dexamethasone

---

Location

United States, Massachusetts